Roche (RHHBY) announced the European Commission has granted marketing authorisation for Tecentriq SC, a PD-L1 cancer immunotherapy for subcutaneous injection. The authorisation applies to all approved indications of Tecentriq IV. Roche said it is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possible.
"We are pleased to introduce the first subcutaneous PD-L1 cancer immunotherapy in Europe," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
Tecentriq SC was first approved in Great Britain in 2023. The approved indications mirror those of Tecentriq IV.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.